ulbi20180730_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 
 

FORM 8-K

 
 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
 

August 2, 2018

(Date of Report)

 
 

ULTRALIFE CORPORATION

(Exact name of registrant as specified in its charter)

 
 

Delaware

000-20852

16-1387013

(State of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

 2000 Technology Parkway, Newark, New York

14513

           (Address of principal executive offices)

(Zip Code)

 

(315) 332-7100

(Registrant’s telephone number, including area code)

 
 
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.  [ ]  

 

Emerging Growth Company [ ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

 

 

 

 

Item 2.02           Results of Operations and Financial Condition

 

On August 2, 2018, Ultralife Corporation issued a press release regarding the financial results for its second quarter ended July 1, 2018. A copy of this press release is attached hereto as Exhibit 99.1.

 

The information set forth in this Form 8-K and the attached exhibit is being furnished to and not filed with the Securities and Exchange Commission and shall not be deemed as incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

 

 

 

Item 9.01     Financial Statements, Pro Forma Financials and Exhibits

 

(d) Exhibits.

 

Exhibit    
Number   Exhibit Description
     

99.1

 

Press Release of Ultralife Corporation dated August 2, 2018

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 2, 2018

 

ULTRALIFE Corporation

     
     
 

By:

/s/ Philip A. Fain

   

Philip A. Fain

   

Chief Financial Officer and Treasurer

 

ex_119397.htm

Exhibit 99.1

 

Company Contact:

Investor Relations Contact:

Ultralife Corporation

LHA

Philip A. Fain

Jody Burfening

(315) 210-6110

(212) 838-3777

pfain@ulbi.com

jburfening@lhai.com

 

 

Ultralife Corporation Reports Second Quarter Results

 

NEWARK, N.Y. – August 2, 2018 -- Ultralife Corporation (NASDAQ: ULBI) reported operating income of $1.6 million on revenue of $22.9 million for the second quarter ended July 1, 2018. For the second quarter of 2017, the Company reported operating income of $1.3 million on revenue of $19.9 million.

 

“Following a solid first quarter, Ultralife delivered second quarter revenue growth of 15% and leveraged operating income growth of 24%.  Second quarter revenue was boosted by a 38% increase in total Company government/defense sales, as spending continued to recover in U.S. government/defense markets, and an 8% increase in medical sales,” said Michael D. Popielec, President and Chief Executive Officer.  “A strong first half, expanding revenue opportunities, and adherence to our business model parameters position us well to deliver another year of profitable growth in 2018.”  

 

 

Second Quarter 2018 Financial Results

 

Revenue was $22.9 million, an increase of $2.9 million, or 14.7%, compared to $19.9 million for the second quarter of 2017 reflecting higher government/defense and medical sales. Battery & Energy Products sales increased $1.0 million, or 5.6%, to $17.8 million compared to $16.9 million last year due primarily to increases in both government/defense and medical sales of 25.0% and 7.8%, respectively, partially offset by lower industrial commercial sales. Communications Systems sales grew 64.5% to $5.0 million compared to $3.1 million for the same period last year reflecting shipments of our Vehicle Installed Power Enhanced Riflemen Appliqué (“VIPER”) and Vehicle Amplifier Adapters for the U.S. Army’s Security Force Assistance Brigades to a large global defense prime contractor.

 

Gross profit was $6.6 million, or 28.6% of revenue, compared to $6.2 million, or 31.2% of revenue, for the same quarter a year ago. Battery & Energy Products’ gross margin was 27.6%, compared to 28.1% last year, and Communications Systems gross margin was 32.3%, compared to 48.4% last year, due to product mix.

 

Operating expenses were $4.9 million for both the 2018 and 2017 quarters reflecting continued tight control over discretionary spending in line with our business model. Operating expenses were 21.5% of revenue compared to 24.6% of revenue for the year earlier period.

 

Operating income was $1.6 million compared to $1.3 million last year.

 

 

 

 

Net income was $1.6 million, or $0.10 per share, compared to net income of $1.1 million, or $0.07 per share, for the second quarter of 2017. Earnings per share for the trailing twelve-month period increased to $.55 compared to $.52 at the end of the first quarter of 2018, with both periods reflecting the $.12 favorable impact of the Tax Cuts and Jobs Act in the fourth quarter of 2017.

 

 

About Ultralife Corporation

 

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.

 

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

 

 

 

Conference Call Information

 

Ultralife will hold its second quarter earnings conference call today at 10:00 AM ET. To participate in the live call, please dial (800) 915-4836 at least ten minutes before the scheduled start time, identify yourself and ask for the Ultralife call. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

 

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: potential reductions in revenues from key customers, uncertain global economic conditions and acceptance of our new products on a global basis. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

 

 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands)

(Unaudited)

 

ASSETS

 
   

July 1,

   

December 31,

 
   

2018

   

2017

 

Current Assets:

 

Cash

  $ 20,749     $ 18,330  

Trade Accounts Receivable, Net

    15,468       14,657  

Inventories

    24,861       26,326  

Prepaid Expenses and Other Current Assets

    2,445       2,603  

Total Current Assets

    63,523       61,916  
                 

Property, Equipment and Improvements, Net

    8,056       7,570  

Goodwill, Intangibles and Other Assets

    27,266       27,700  

Total Assets

  $ 98,845     $ 97,186  
                 

LIABILITIES AND SHAREHOLDERS' EQUITY

 
                 

Current Liabilities:

 

Accounts Payable

  $ 6,656     $ 8,787  

Accrued Compensation and Related Benefits

    1,711       2,413  

Accrued Expenses and Other Current Liabilities

    2,487       3,039  

Total Current Liabilities

    10,854       14,239  

Deferred Income Taxes and Other Non-Current Liabilities

    3,923       3,898  

Total Liabilities

    14,777       18,137  
                 

Shareholders' Equity:

 

Common Stock

    1,996       1,966  

Capital in Excess of Par Value

    181,818       180,211  

Accumulated Deficit

    (79,117 )     (82,894 )

Accumulated Other Comprehensive Loss

    (2,036 )     (1,611 )

Treasury Stock

    (18,469 )     (18,469 )

Total Ultralife Equity

    84,192       79,203  

Non-Controlling Interest

    (124 )     (154 )

Total Shareholders’ Equity

    84,068       79,049  
                 

Total Liabilities and Shareholders' Equity

  $ 98,845     $ 97,186  

 

 

 

 

ULTRALIFE CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(In Thousands Except Per Share Amounts)

(Unaudited)

 

   

Three-Month Periods Ended

   

Six-Month Periods Ended

 
   

July 1,

   

July 2,

   

July 1,

   

July 2,

 
   

2018

   

2017

   

2018

   

2017

 

Revenues:

                               

Battery & Energy Products

  $ 17,831     $ 16,880     $ 35,055     $ 34,359  

Communications Systems

    5,033       3,059       10,878       7,615  

Total Revenues

    22,864       19,939     $ 45,933     $ 41,974  
                                 

Cost of Products Sold:

                               

Battery & Energy Products

    12,905       12,139       25,093       24,688  

Communications Systems

    3,409       1,579       7,008       4,175  

Total Cost of Products Sold

    16,314       13,718       32,101       28,863  
                                 

Gross Profit

    6,550       6,221       13,832       13,111  
                                 

Operating Expenses:

                               

Research and Development

    1,218       1,185       2,318       2,323  

Selling, General and Administrative

    3,700       3,714       7,526       7,625  

Total Operating Expenses

    4,918       4,899       9,844       9,948  
                                 

Operating Income

    1,632       1,322       3,988       3,163  
                                 

Other (Income) Expense

    (86 )     49       48       142  

Income Before Income Tax Provision

    1,718       1,273       3,940       3,021  
                                 

Income Tax Provision

    78       179       133       266  
                                 

Net Income

    1,640       1,094       3,807       2,755  
                                 

Net Income Attributable to Non-Controlling Interest

    13       -       30       6  
                                 

Net Income Attributable to Ultralife Corporation

  $ 1,627     $ 1,094     $ 3,777     $ 2,749  
                                 
                                 

Net Income Per Share Attributable to Ultralife Common Shareholders – Basic

  $ .10     $ .07     $ .24     $ .18  
                                 

Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted

  $ .10     $ .07     $ .23     $ .17  
                                 

Weighted Average Shares Outstanding – Basic

    15,922       15,510       15,813       15,461  
                                 

Weighted Average Shares Outstanding – Diluted

    16,520       15,850       16,354       15,752